Symposium at IAS 2025: How Long-acting Drugs Can Help End the HIV Pandemic in Africa

About the program

This 60-minute symposium will provide clinicians and healthcare professionals caring for people living with HIV with timely and practical insights into long-acting injectable antiretroviral therapy for treatment and prevention. The program will cover the long-term impact of CAB LA for PrEP in Africa, new 96 week data from the CARES study on switching virally suppressed patients to long-acting CAB and RPV, and the role of injectables in preventing HIV infection in adolescents based on the HPTN 084 1 trial. A panel discussion and audience Q&A will focus on translating these findings into practice by addressing barriers and promoting equitable access. This session is highly relevant for those involved in HIV care and program delivery in resource-limited settings.